Rosetta Genomics Receives Additional U.S. Patent Protection for the Cancer Origin Test™

Composition of matter patent protects a core element of its diagnostic assay for the accurate identification of the tissue of origin in cancers of unknown or uncertain primary

PRINCETON, N.J. & REHOVOT, Israel--()--Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular and other diagnostics, announces that the Company has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application No. 13/986,516 titled, “microRNAs and uses thereof.”

“Our growing intellectual property position continues to protect and solidify our global leadership position in microRNA biomarker technology while providing additional revenue generating opportunities for us and enhancing our leadership position in the commercialization of differentiated and proprietary content in the area of personalized medicine.”

The composition of matter patent claims hsa-miR-509-3p, its complement and a sequence at least 90% identical to it, as well as a primer and a vector comprising this microRNA. This patent specifically covers one essential marker in the Rosetta Cancer Origin Test™.

“We continue to make inroads building patent protection around our microRNA technology platforms and products. This new patent allowance further strengthens and secures the coverage for one of our lead products, the Rosetta Cancer Origin Test™, which can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary,” said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “Our growing intellectual property position continues to protect and solidify our global leadership position in microRNA biomarker technology while providing additional revenue generating opportunities for us and enhancing our leadership position in the commercialization of differentiated and proprietary content in the area of personalized medicine.”

Rosetta Genomics has 42 issued patents, seven allowed patents and 43 patents pending worldwide.

About Rosetta Cancer Testing Services

Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The Rosetta Lung Cancer Test accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. Rosetta’s assays are designed to provide objective diagnostic data. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test, 62,000 from the Rosetta Kidney Cancer Test™ and 222,000 patients from the Rosetta Lung Cancer Test. The Company’s assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. In addition to its proprietary products, the Company markets the Rosetta Genomics PGxOneand EGFR and KRAS tests for Admera Health. With the recent acquisition of PersonalizeDx, the company now offers a broader menu of molecular and other assays for bladder, lung, prostate and breast cancer patients. For more information, please visit www.rosettagenomics.com. Parties interested in ordering any of these tests can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. PersonalizeDx’s core FISH, IHC and PCR-based testing capabilities and partnerships in oncology and urology provide additional content and platforms that complement the Rosetta offerings. Rosetta’s and PersonalizeDx’s cancer testing services are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the patent protecting a core element of Rosetta's Cancer Origin Test™, Rosetta building patent protection around Rosetta's microRNA technology platforms and products, Rosetta's commercial potential, and Rosetta's intellectual property position providing additional revenue generating opportunities,, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contacts

Company Contacts:
Rosetta Genomics
Ken Berlin, 609-419-9003
President & CEO
investors@rosettagenomics.com
or
Investor Contacts:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Recent Stories

RSS feed for Rosetta Genomics Ltd.

Rosetta Genomics Ltd.